AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

Q4 Biopharma Themes: Strong 2018, Weaker 2019 Earnings Projections, Concerns Over Drug Pricing

Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.

February 1, 2019

5 min read

Mark Terry

Lumasiran was granted priority review status by FD

Business

FDA Gives Greenlight to Janssen and AbbVie’s Imbruvica for the 10th Time

The approval of the combination marks a first for the U.S. market. The combination of AbbVie and Janssen’s Imbruvica with Roche’s Gazyva is the first chemotherapy-free, anti-CD20 combination to treat CLL and SLL patients who have not yet started therapy, AbbVie said this morning.

January 28, 2019

2 min read

Alex Keown

Business

AbbVie’s 2018: Revenues up, Earnings Down as Company Enters “Important New Phase”

AbbVie reported a loss of $1.83 billion for the fourth quarter of 2018. Overall revenues were up for the full year, however, hitting $32.75 billion compared to $28.2 billion in 2017.

January 25, 2019

2 min read

Mark Terry

Drug Development

AbbVie’s ‘s Imbruvica Fails to Gain Traction in Pancreatic Cancer

The company provided an update on its Phase III trial of Imbruvica in combination with chemotherapy compared to placebo in metastatic pancreatic adenocarcinoma.

January 21, 2019

3 min read

Mark Terry

FDA

Who’s the Boss? Companies and Their Novel Drug Approvals, 2014-2018

In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.

January 15, 2019

5 min read

Mark Terry

Policy

House Oversight Committee Takes on Pharma Industry

It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.

January 15, 2019

2 min read

Alex Keown

Employer Resources

Top 10 Cities in the U.S. for the Job Market

New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.

January 14, 2019

3 min read

Mark Terry

Policy

M&A May Be the Legacy of the Trump Tax Cuts for Pharma

Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.

January 8, 2019

3 min read

Alex Keown

Business

AbbVie Forges $105 Million+ CD39 Inhibitor Alliance With Tizona

Privately-held Tizona Therapeutics snagged $105 million in upfront cash as its cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.

January 4, 2019

2 min read

Alex Keown

JOBS